Source: Bloom Health Partners.
  • Bloom Health (BLMH) has announced a COVID rapid and lab testing contract with K-12 schools in Texas
  • The state-wide contract is for the remainder of the 2022 school year
  • The company can accommodate high volume by ramping up to 24-hour turnarounds
  • Bloom Health Partners offers a global platform for health care security, diagnostic testing and occupational health-tech
  • Bloom Health (BLMH) is up by 22.86 per cent trading at $0.43 per share

Bloom Health (BLMH) has announced a COVID rapid and lab testing contract with K-12 schools in Texas.

The state-wide contract is for the remainder of the 2022 school year.

It will supply rapid tests to schools directly and manage results on its cloud data platform.

It will process RT-PCR tests at its laboratory in Dallas, which is equipped for 24-hour turnarounds.

As per state regulations, testing is available to students on a voluntary basis.

The contract is supported by the U.S. Department of Health and Human Services’ National Testing Action Program.

“Effective and reliable testing is critical to keeping schools safe and operational,” said Andrew Morton, CEO of Bloom Health. “As an occupational health-tech provider, our team is well equipped to work with schools in Texas on a successful program.”

Bloom Health Partners offers a global platform for health care security, diagnostic testing and occupational health tech.

Bloom Health (BLMH) is up by 22.86 per cent trading at $0.43 per share as of 1:43 pm EST.

More From The Market Online
POET - POET's dual LR4 transmit optical engine created for ADVA.

POET Technologies stock takes flight after Foxconn deal

Foxconn Interconnect Technology picks POET Technologies (TSXV:PTK) to provide optical engines for 800G and 1.6T optical transceiver modules.

Edgewater Wireless files patent application for spectrum slicing

Edgewater Wireless Systems (TSXV:YFI) completes a patent application with the U.S. Patent and Trademark Office for spectrum slicing.

UniDoc brings AI to ER patients

UniDoc (CSE:UDOC) expands its AI partnership with DocBox, further integrating predictive analytics into emergency room operations.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.